for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

China Biologic Products Holdings Inc

CBPO.OQ

Latest Trade

114.20USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

60.09

 - 

115.48

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
114.20
Open
--
Volume
--
3M AVG Volume
3.11
Today's High
--
Today's Low
--
52 Week High
115.48
52 Week Low
60.09
Shares Out (MIL)
38.26
Market Cap (MIL)
4,369.73
Forward P/E
25.51
Dividend (Yield %)
--

Next Event

Q3 2019 China Biologic Products Holdings Inc Earnings Release

Latest Developments

More

China Biologic Announces Receipt Of Preliminary Non-Binding "Going Private" Proposal

China Biologic Reports Q2 2019

China Biologic Products Says Unit Enters Agreement With Fujian Pingtan & Xinyu Yongshuo

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About China Biologic Products Holdings Inc

China Biologic Products Holdings, Inc. is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company's products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).

Industry

Biotechnology & Drugs

Contact Info

+86.10.65983111

http://www.chinabiologic.com

Key Stats

3.40 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.3K

2017

0.4K

2018

0.5K

2019(E)

0.5K
EPS (USD)

2016

4.520

2017

4.950

2018

4.020

2019(E)

4.476
Price To Earnings (TTM)
31.84
Price To Sales (TTM)
8.75
Price To Book (MRQ)
2.57
Price To Cash Flow (TTM)
23.48
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
11.19
Return on Equity (TTM)
9.55

Latest News

UPDATE 1-China Biologic receives offer to be taken private at $120 a share

China Biologic Products Holdings Inc said on Wednesday it had received an offer from a consortium of buyers that will pay $1.93 billion in cash to buy shares that they do not already own to take the company private.

China Biologic receives $4.59 billion take-private buyout offer

China Biologic Products Holdings Inc <CBPO.O> said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers.

China Biologic rejects $3.9 billion bid from former CEO

China Biologic Products Holdings Inc <CBPO.O> rejected a $3.9 billion offer from a consortium led by its former chief executive on Friday and said an affiliate of CITIC Capital had also withdrawn a competing bid.

China Biologic rejects former CEO-led consortium's offer

China Biologic Products Holdings Inc said on Friday it had rejected an offer from a consortium led by its former chief executive and the company said an affiliate of CITIC Capital unit had withdrawn a competing offer.

China Biologic gets $3.9 billion offer from former CEO-led consortium

China Biologic Products Holdings Inc <CBPO.O> on Monday received a $3.9 billion all-cash offer from a consortium of investment firms, valuing the Beijing-based company at slightly above an earlier buyout proposal from a CITIC Capital unit.

CORRECTED-UPDATE 1-China Biologic gets $3.9 bln offer from former CEO-led consortium

China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium of investment firms led by the company's former chief executive David Gao.

CORRECTED-China Biologic gets $3.9 bln offer from former CEO-led consortium

China Biologic Products Holdings Inc on Monday received a $3.9 billion all-cash offer from a consortium that included company's former chief executive, GL Capital Group, Bank of China Group Investment Limited and CDH Investments.

BRIEF-China Biologic Reports Q4 Adjusted Non-GAAP Earnings Per Share $0.90

* CHINA BIOLOGIC REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FISCAL YEAR 2017

BRIEF-China Biologic To Build New Collection Station In Hainan Province

* CHINA BIOLOGIC TO BUILD NEW COLLECTION STATION IN HAINAN PROVINCE

BRIEF-Marc Chan Reports 9.5 Percent Passive Stake In China Biologic Products Holdings As Of Dec 31, 2017

* MARC CHAN REPORTS 9.5 PERCENT PASSIVE STAKE IN CHINA BIOLOGIC PRODUCTS HOLDINGS INC AS OF DEC 31, 2017 - SEC FILING Source text - (http://bit.ly/2CffxTI) Further company coverage:

BRIEF-China Biologic Receives Operating Permit For New Collection Facility In Ju County In Shandong Province

* CHINA BIOLOGIC RECEIVES OPERATING PERMIT FOR NEW COLLECTION FACILITY IN JU COUNTY IN SHANDONG PROVINCE Source text for Eikon: Further company coverage:

BRIEF-China Biologic posts Q3 adj. earnings per share $1.38

* China Biologic reports unaudited financial results for the third quarter of 2017

BRIEF-China Biologic agrees to acquire Tianxinfu from PWM

* China Biologic Products Holdings Inc - It has agreed to acquire 80% equity interest in Tianxinfu (Beijing) Medical Appliance Co., Ltd

BRIEF-China Biologic receives approval for commercial manufacturing of human fibrinogen

* China Biologic receives approval for commercial manufacturing of human fibrinogen

BRIEF-China Biologic Q2 earnings per share $1.09

* China Biologic reports financial results for the second quarter of 2017

BRIEF-China Biologic reports Q1 earnings per share $1.06

* China Biologic reports financial results for the first quarter of 2017

BRIEF-China Biologic Q4 adjusted non-GAAP earnings per share $0.95

* China Biologic reports financial results for the fourth quarter and fiscal year 2016

BRIEF-Baillie Gifford & Co reports 5.21 pct passive stake in China Biologic Products

* Baillie Gifford & Co reports 5.21 percent passive stake in China Biologic Products Inc as of december 31 - sec filing Source text : http://bit.ly/2jfbYrf Further company coverage:

BRIEF-China Biologic to build new collection station in Shandong province

* China Biologic to build new collection station and new branch collection facility in Shandong province

BRIEF-China Biologic reports Q3 adj non-gaap earnings per share $1.22

* Raises full year 2016 revenue and adjusted net income forecast

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up